Please assess the completion status of the following clinical trial:

Trial Title: A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Symptomatic PAH belonging to one of the following types:~  * Idiopathic~ * Heritable~ * Drug- or toxin- induced~ * Associated with one of the following: connective tissue disease or congenital heart disease~* World Health Organization (WHO) Functional Class (FC) II or III~* PAH diagnosed by right heart cardiac catheterization prior to Screening~* Receiving standard of care treatment for PAH with oral monotherapy or dual therapy for at least 12 weeks prior to Screening at a dose which has been stable for at least 8 weeks prior to Screening~* If on a diuretic, dose must be stable for at least 4 weeks prior to Screening, with no changes anticipated during study participation~* 6-Minute Walk Distance (6MWD) between 150 and 500 meters at Screening and Baseline visits~* Plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) level ≥ 300 pg/mL at Screening~* Ability and willingness to give written informed consent and to comply with the requirements of the study~Key Exclusion Criteria:~* PAH associated with human immunodeficiency virus (HIV) infection, portal hypertension or schistosomiasis~* Other types of pulmonary hypertension (PH):~  * Pulmonary hypertension due to left heart disease (WHO PH Group 2)~ * Pulmonary hypertension due to lung diseases and/or hypoxia (WHO PH Group 3)~ * Chronic thromboembolic pulmonary hypertension (WHO PH Group 4)~ * Pulmonary hypertension with unclear multifactorial mechanisms (WHO PH Group 5)~* Hospitalization for pulmonary hypertension within 12 weeks of screening~* Cardiopulmonary rehabilitation program based on exercise (planned, or started ≤ 12 weeks prior to Screening)~* Prostanoid or prostacyclin receptor agonist therapy within 12 weeks of screening~* Evidence of left-sided heart disease~* If Pulmonary function tests were done prior to screening, Pulmonary function tests demonstrate obstructive or restrictive lung disease~* Use of telotristat (Xermelo®) within the last 6 months~* Use of any investigational drug within 30 days or five half-lives (whichever is longer) prior to Screening, or 90 days if an investigational drug for PAH~* Have uncontrolled atrial fibrillation (AFib) or other uncontrolled arrhythmias~* Body mass index (BMI) \>45 kg/m2~* Women of childbearing potential who are pregnant, planning to become pregnant, or lactating or female/male patients unwilling to use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RVT-1201 (Type: EXPERIMENTAL): RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 \[Anticipated\])
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 \[Anticipated\])

Based on this trial design, predict the completion outcome and termination type (if applicable).